Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.56 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.54 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.54 |
| ▸ | PDK3 | Q15120 | 2/20 | 0.54 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 5/20 | 0.51 |
| ▸ | NPC1 | O15118 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 5/20 | 0.51 |
| ▸ | KDR | P35968 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15072457 | 0.85 | KMT2A (0.58) | KMT2APDK1PDK2PDK3PDK4 | |
| SCHEMBL3792617 | 0.84 | KMT2A (0.58) | KMT2APDK1PDK2PDK3PDK4 | |
| SCHEMBL31718129 | 0.83 | PDK1 (0.69) | KMT2APDK1PDK2PDK3PDK4 | |
| SCHEMBL14254877 | 0.83 | HTT (0.60) | RAB9ANPC1SMN1; SMN2MAPTLMNA | |
| SCHEMBL14254880 | 0.83 | PDK1 (0.69) | KMT2APDK1PDK2PDK3PDK4 | |
| SCHEMBL18088737 | 0.81 | POLB (0.58) | KMT2APDK1PDK2PDK3PDK4 | |
| SCHEMBL3873599 | 0.81 | KDM4E (0.62) | KMT2ARAB9ANPC1SMN1; SMN2HPGD | |
| SCHEMBL29683063 | 0.81 | KDM4E (0.62) | KMT2ARAB9ANPC1SMN1; SMN2HPGD | |
| SCHEMBL19707984 | 0.80 | KMT2A (0.66) | KMT2ARAB9ANPC1SMN1; SMN2HPGD | |
| SCHEMBL16992886 | 0.80 | RAB9A (0.51) | KMT2APDK1PDK2PDK3PDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1359147-A1 | 4,4-disubstituted-1,4-dihydro-2H-3,1-benzoxazin-2-ones useful as HIV reverse transcriptase inhibitors and processes for making the same | Bristol-Myers Squibb Pharma Company (US) | 2003-11-05 | — | — | EP | disclosed |
| EP-0929533-B1 | 4,4-DISUBSTITUTED-1,4-DIHYDRO-2H-3,1-BENZOXAZIN-2-ONES USEFUL AS HIV REVERSE TRANSCRIPTASE INHIBITORS AND INTERMEDIATES AND PROCESSES FOR MAKING THE SAME | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2003-09-03 | — | — | EP | disclosed |
| US-6492515-B2 | FOR THERAPY OF HIV INFECTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-12-10 | — | — | US | disclosed |
| US-20020040138-A1 | 4,4-disubstituted-1, 4-dihydro-2H-3, 1-benzoxazin-2-ones useful as HIV reverse transcriptase inhibitors and intermediates and processes for making the same | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-04-04 | — | — | US | disclosed |
| US-6303780-B1 | 4,4-disubstituted-1,4-dihydro-2h-3,1-benzoxazin-2-ones useful as HIV reverse transcriptase inhibitors and intermediates and processes for making the same | DUPONT PHARMACEUTICALS COMPANY | 2001-10-16 | — | — | US | disclosed |
| US-6140499-A | 4,4-disubstituted-1,4-dihydro-2H-3,1-benzoxazin-2-ones useful as HIV reverse transcriptase inhibitors and intermediates and processes for making the same | DUPONT PHARMACEUTICAL COMPANY (US) | 2000-10-31 | — | — | US | disclosed |
| US-5874430-A | COMPOUNDS AS PROTEASE, REVERSE TRANSCRIPTASE INHIBITORS FOR DIAGNOSIS | DUPONT PHARMACEUTICALS COMPANY (US) | 1999-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040138-A1 | 4,4-disubstituted-1, 4-dihydro-2H-3, 1-benzoxazin-2-ones useful as HIV reverse transcriptase inhibitors and intermediates and processes for making the same | DHX15, CYP4X1, DPYD | KMT2A 1787/4885PDK1 1645/4885PDK2 979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.